Andrew Bryant
Jan Lecouturier
Giovany Orozco Leal
Dr Vicky Brocklebank
Dr Sonya Carnell
et al. | Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial | 2025 |
|
Emily Glover
Dr Emma Montgomery
Dr Edwin Wong
Dr Michal Malina
Professor Kevin Marchbank
et al. | Late onset thrombotic microangiopathy in kidney transplants; poor outcome despite eculizumab treatment | 2025 |
|
Professor David Kavanagh
Dr Edwin Wong
| Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study | 2025 |
|
Laura Bailey
Vikki Bridgett
Dr Vicky Brocklebank
Dr Sally Johnson
Professor David Kavanagh
et al. | Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR Registry | 2025 |
|
Giovany Orozco Leal
Professor Luke Vale
Dr Vicky Brocklebank
Andrew Bryant
Dr Thomas Chadwick
et al. | The cost-effectiveness of replacing lifelong therapy of eculizumab with a strategy of disease monitoring for eligible atypical haemolytic uraemic syndrome (aHUS) patients: an economic evaluation of the SETS aHUS trial | 2025 |
|
Dr Sally Johnson
Professor David Kavanagh
Professor John Sayer
Dr Edwin Wong
Megan Bates
et al. | Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort | 2024 |
|
Dr Sally Johnson
Dr Edwin Wong
| Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group | 2024 |
|
Dr Sally Johnson
Professor David Kavanagh
Professor John Sayer
Dr Edwin Wong
Dr Vicky Brocklebank
| Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort | 2024 |
|
Dr Edwin Wong
| Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy | 2024 |
|
Dr Edwin Wong
Lee-Ann Naidoo
Sarah Winn
Dr Patrick Walsh
Dr Vicky Brocklebank
et al. | The Annual Report of the National Renal Complement Therapeutics Centre 2022/23 | 2024 |
|
Emily Glover
Dr Kate Smith-Jackson
Dr Vicky Brocklebank
Dr Valerie Wilson
Dr Patrick Walsh
et al. | Assessing the Impact of Prophylactic Eculizumab on Renal Graft Survival in Atypical Hemolytic Uremic Syndrome | 2023 |
|
Dr Vicky Brocklebank
Dr Patrick Walsh
Dr Kate Smith-Jackson
Dr Thomas Hallam
Professor Kevin Marchbank
et al. | Atypical haemolytic uraemic syndrome in the era of terminal complement inhibition- An observational cohort study | 2023 |
|
Dr Edwin Wong
Professor David Kavanagh
| Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy | 2023 |
|
Dr Ruyue Sun
Dr Long Xie
Rebecca Russell
Dr Edwin Wong
Professor Neil Sheerin
et al. | Pre-eclampsia is associated with complement pathway activation in the maternal and fetal circulation, and placental tissue | 2023 |
|
Dr Edwin Wong
Sarah Winn
Dr Michal Malina
Dr Sally Johnson
Professor Neil Sheerin
et al. | The Annual Report of the National Renal Complement Therapeutics Centre 2021/22 | 2023 |
|
